Product Development

Challenge: An early-stage biotechnology startup company reached out to Alacrita for critical support of its two lead AAV-delivered gene therapy programs. As a virtual company, the client needed...

Challenge A European company developing novel antiviral drugs urgently needed an experienced pharmaceutical physician to work as an interim CMO, as the predecessor was about to move into a leadership...

Challenge: A biotech company developing novel gene therapy approaches for in vivo cell trans-differentiation required an AAV gene therapy expert to serve on a scientific advisory board (SAB) tasked...

Challenge: A venture-backed US biotech company was developing a preclinical biologic for haematological indications and wished to quantify the commercial opportunity for the product in treating...

Challenge: Alacrita was asked to assess a novel mAB-based approach to suppressing cancer metastases. The client, a biotech incubator with rights to the project, was considering further investment,...

Challenge: A European pharmaceutical company focussed on ophthalmic care was seeking Well Established Use (WEU) approval in Europe for a small molecule asset. The company commissioned Alacrita to...

Challenge: A research-focused biotech company developing a novel, first-in-class, next generation oral anticoagulant for the prevention of life-threatening thrombotic events asked Alacrita to...

Challenge: An in-silico drug discovery company requested an expert review of the robustness and potential positioning of a new kinase inhibitor in oncology and inflammatory disease. Alacrita was...

Challenge: A cell and gene therapy platform company developing a scalable AAV production system, requested Alacrita’s guidance on the priority order for AAV vector capsid serotype release and the...

Challenge: A biopharmaceutical company developing novel immunomodulatory technology was exploring the potential clinical use of its lead candidate in combination with AAV based gene therapies to...

Challenge: Our client, a major generics and biosimilars player, was developing a generic version of a major therapeutic. It had submitted a dossier for marketing authorization in the EU which was...

Challenge: Our client was developing oncolytic viruses for treating a rare form of brain cancer. Its lead product had been successfully evaluated in a Phase I dose-escalation study. Direct injection...